pdf   xlsx method abbreviations

metastatic/advanced - colorectal cancer (mCRC), durvalumab based treatment , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

DCR 0.80 [0.17, 3.71]> 10%1 study (1/-)38.8 %NAnot evaluable non important-
objective responses (ORR) 1.80 [0.54, 6.02]> 10%1 study (1/-)82.9 %NAnot evaluable non important-

safety endpoints 00

AE leading to death (grade 5) 3.26 [0.32, 33.62]< 10%1 study (1/-)16.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.